Hand Eczema

ORLANDO — A subset of patients treated with delgocitinib cream 20 mg/g for moderate to severe chronic hand eczema achieved a “super-response,” by week 16, according to a presenter at the American Academy of Dermatology Annual Meeting.

The new drug application for delgocitinib cream 2% has been accepted by the FDA for the treatment of patients with moderate to severe chronic hand eczema, LEO Pharma announced in a press release.

A new study finds that the majority of patients with chronic hand eczema suffer from corticosteroid phobia, which negatively impacts treatment adherence.

Delgocitinib cream has shown efficacy in the treatment of hand eczema in two phase 3 trials.

The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended the approval of Anzupgo for the treatment of chronic hand eczema in adults, LEO Pharma announced in a press release.

Delgocitinib cream demonstrated superiority to alitretinoin capsules in the treatment of severe chronic hand eczema, LEO Pharma announced in a press release.

New data showed delgocitinib cream maintained symptom relief and treatment success in adults with chronic hand eczema, LEO Pharma announced in a press release.

Tape strips that capture the molecular fingerprint of chronic hand eczema indicated broadly shared immune and barrier dysregulations among patients who have and who do not have atopic dermatitis, according to a study abstract.

The European Medicines Agency has validated the marketing authorization application for delgocitinib cream for moderate to severe chronic hand eczema treatment, LEO Pharma announced in a press release.

Gusacitinib significantly outperformed placebo, showing a tolerable safety profile and a rapid improvement in the treatment of patients with chronic hand eczema, according to a phase 2 study.